Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Gynecologic 1Gastrointestinal 1

Conditions

Neoplasm Metastasis 2Uterine Cervical Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Mesothelioma 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Gliosarcoma 1Glioma 1Glioblastoma 1Brain Neoplasms 1

Interventions

pembrolizumab 17Cisplatin 11Carboplatin 9Cyclophosphamide 8fludarabine 6Paclitaxel 6Nivolumab 6Bevacizumab 6aldesleukin 5Radiotherapy 5toripalimab 4tisotumab vedotin 4fludarabine phosphate 4Topotecan 4Interleukin-2 4Docetaxel 4Brachytherapy 4spartalizumab 3Ipilimumab 3Fulvestrant 3ferumoxtran-10 2enzalutamide 2durvalumab 2cemiplimab 2bemarituzumab 2balstilimab 2Trastuzumab 2Radiation 2Magnetic Resonance Spectroscopy 2Injections 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Uterine Cervical Neoplasms × Automobiles × Clear all
NCT01583686 2019-10-14

CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
15 enrolled 14 charts
GastrointestinalGynecologicOther solid neoplasmThoracic

Uterine Cervical Neoplasms, Lung Neoplasms, Mesothelioma, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡